<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="75747">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02156544</url>
  </required_header>
  <id_info>
    <org_study_id>148HPS14001</org_study_id>
    <nct_id>NCT02156544</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519</brief_title>
  <acronym>CKD-519 FIH</acronym>
  <official_title>A Dose-block Randomized, Double-blind, Placebo-controlled, Single Dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519 After Oral Administration in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety/tolerability and
      pharmacokinetics/pharmacodynamics of CKD-519.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Cmax of CKD-519</measure>
    <time_frame>0(predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 32, 48, 72, 96, 120, 144, 168</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-last of CKD-519</measure>
    <time_frame>0(predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 32, 48, 72, 96, 120, 144, 168</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-âˆž of CKD-519</measure>
    <time_frame>0(Predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 32, 48, 72, 96, 120, 144, 168</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of CKD-519</measure>
    <time_frame>0(Predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 32, 48, 72, 96, 120, 144, 168</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 of CKD-519</measure>
    <time_frame>0(Predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 32, 48, 72, 96, 120, 144, 168</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F of CKD-519</measure>
    <time_frame>0(Predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 32, 48, 72, 96, 120, 144, 168</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Vd/F of CKD-519</measure>
    <time_frame>0(Predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 32, 48, 72, 96, 120, 144, 168</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>CETP activity</measure>
    <time_frame>0(Predose), 0.5, 1, 2, 4, 8, 18, 24, 48, 72, 96, 120, 144, 168</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>CKD-519 25mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CKD-519 25mg or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CKD-519 50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CKD-519 50mg or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CKD-519 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CKD-519 100mg or  placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CKD-519 200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CKD-519 200mg or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CKD-519 400mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CKD-519 400mg or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-519</intervention_name>
    <arm_group_label>CKD-519 25mg</arm_group_label>
    <arm_group_label>CKD-519 50mg</arm_group_label>
    <arm_group_label>CKD-519 100mg</arm_group_label>
    <arm_group_label>CKD-519 200mg</arm_group_label>
    <arm_group_label>CKD-519 400mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>CKD-519 25mg</arm_group_label>
    <arm_group_label>CKD-519 50mg</arm_group_label>
    <arm_group_label>CKD-519 100mg</arm_group_label>
    <arm_group_label>CKD-519 200mg</arm_group_label>
    <arm_group_label>CKD-519 400mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Between 19 aged and 55 aged in healthy adult

          2. Body weight more than 55kg in male, 50kg in female

          3. Body Mass Index more than 18.5 and under 25(body mass index=kg/m2)

          4. If female, must include more than one among the items

               -  The menopause(there is no natural menses for at least 2 years)

               -  Surgical Infertility(hysterectomy or bilateral oophorectomy, tubal ligation or
                  other methods of infertility condition

          5. If men has sexual life with women of childbearing age, Necessarily he agrees that use
             condoms and do not sperm donation until two months during clinical trials and after
             the final dosage of investigational products

          6. Those who fully understand about this clinical trials after enough hearing, and then
             decided to join the clinical trials by themselves and to comply with the precautions
             written consent

        Exclusion Criteria:

          1. Have clinically significant disease that hepatobiliary system(severe hepatic
             impairment, etc), kidney(severe renal impairment, etc), nervous system, immune
             system, respiratory system, endocrine system, hemato-oncology disease, cardiovascular
             system(heart failure, etc) or mental illness, or a history of mental disease.

          2. Have a gastrointestinal disease history that can effect drug absorption(Crohn's
             disease, ulcers, etc.) or surgery(except simple appendectomy or hernia surgery)

          3. Hypersensitivity reaction  or clinically significant hypersensitivity reaction in the
             history of drugs or additives.

          4. An impossible one who participates in clinical trial including screening
             tests(medical history taking, BP, 12-lead ECG, physical examination, blood&amp;urine
             laboratory test result) before 28 days the taking investigational Products.

          5. Defined by the following laboratory parameters

               -  AST, ALT&gt;1.25* upper limit of normal range

               -  Total bilirubin&gt;1.5* upper limit of normal range

               -  CPK&gt;1.5* upper limit of normal range

               -  eGFR(using by MDRD method)&lt;60mL/min/1.73m2

          6. Sitting SBP&gt;150mmHg or &lt;90mmHg, sitting DBP&gt;100mmHg or &lt;50mmHg, after 5 minutes
             break.

          7. Drug abuse or have a history of drug abuse showes a positive for urine drug test.

          8. Pregnant or lactating women.

          9. A heavy caffeine consumer(caffeine&gt;5 cups/day), alcohol consumer(alcohol&gt;210g/week),
             or smoker(cigarette&gt;10 cigarettes/day)

         10. Subject takes ethical drug or herbal medicine within 14 days, OTC within 7 days
             before the beginning of study treatment but investigator determine that the taking
             drug affect this study or could affect the safety of subjects.

         11. Subject who takes inhibitor and inducers of drug metabolizing enzyme(Barbiturates
             etc.) within 30 days.

         12. Taking foods containing grapefruit within 7 days before the beginning of study
             treatment(ex. Drinking containing grapefruit of 1L per a day or more within 7 days
             before the beginning of study treatment)

         13. Subject who treated with any investigational drugs within 60 days before the
             beginning of study treatment(However, biologicals applies for 90 days, but can be
             based on a more extended period of time by considering the half-life)

         14. Previously donate whole blood within 60 days or component blood within 30 days.

         15. An impossible one who participants in clinical trial by investigator's decision
             including laboratory test result or another reason.

         16. Positive for Serology test(Hepatitis B, Hepatitis C, HIV)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min-Su Park, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Min-Su Park, Ph.D</last_name>
    <phone>+82-2-2228-0400</phone>
    <email>minsupark@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Seodaemun-gu</state>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Min-Su Park, Ph.D</last_name>
      <phone>+82-2-2228-0400</phone>
      <email>minsupark@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Min-Su Park, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>June 3, 2014</lastchanged_date>
  <firstreceived_date>June 1, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
